



Intercell starts pivotal Phase III clinical trials of Japanese Encephalitis Vaccine

Vienna, Austria, September 19, 2005 – Intercell AG (VSE, “ICLL”) announced today the start of global multi-center Phase III clinical trials of its Japanese Encephalitis vaccine, IC51. Japanese Encephalitis (JE) is a mosquito-borne flaviviral infection and the leading cause of viral encephalitis in Asia. The infection is a major health problem throughout Asia where 3 billion people live in JE-endemic areas. A safe and efficacious traveler vaccine for tourists visiting Asian countries will meet a high unaddressed medical need.

The global phase III program consists of a series of immunogenicity and safety trials, and will enroll more than 4,900 subjects. Furthermore, a one time vaccination schedule is included in the Phase III program.

The immunogenicity studies will take place in Austria, Germany and the United States. The study is designed to demonstrate non-inferiority of the Intercell vaccine compared to JE-VAX®. JE-VAX® is the only Japanese Encephalitis vaccine approved in the US. The trial will compare the ability of IC51 and JE-VAX® to elicit seroconversion. The first individuals in this pivotal immunogenicity trial have received their first vaccinations today. So far, about 300 subjects have already been enrolled for the Phase III program.

An additional series of Phase III trials will gather further immunogenicity and safety data in approximately 4,000 subjects. These subjects will be recruited in Austria, Australia, Bulgaria, Germany, Israel, the Netherlands, New Zealand, Romania, UK and the United States.

The clinical trial material for the Phase III Studies is produced according to GMP standards in Intercell’s own manufacturing plant in Livingston, Scotland.

“The start of the pivotal clinical trials, which is fully supported by the respective regulatory authorities, demonstrates again Intercell’s very strong commitment and capability to develop innovative vaccines”, states Gerd Zettlmeissl, Chief Operating Officer of Intercell AG.

“Our lead product is fully on track towards registration and market introduction.”

First results of these trials are expected in mid 2006. License applications will then be made for the US, EU and Australia.

About Intercell’s JE vaccine

Intercell’s novel Japanese Encephalitis vaccine is a purified, inactivated vaccine for active immunization of adults against the Japanese Encephalitis virus and has successfully concluded Phase II clinical trials.

In a Phase II head-to-head comparison with JE-VAX®, Intercell’s vaccine was shown to be:

- » More potent - higher antibody levels at all doses studied one month after the immunizations; this vaccine also showed high seroconversion rates one month after a single dose





- » More convenient - 2 doses versus 3 doses and liquid versus freeze-dried format
- » More persistent – higher persistence of antibodies two years after primary immunization
- » Less reactogenic - both in frequency and intensity

Intercell's focus is to make this product available to travellers and military personnel from the EU and the US to endemic areas. Furthermore it has recently concluded strategic alliances with Biological E and CSL Ltd. to market the product in Asia and Australia, respectively, where the disease is endemic.

About Intercell

Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prophylaxis and treatment of diseases with substantial unaddressed medical need. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis undergoing Phase III clinical trials, a vaccine for Hepatitis C in Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communication

Campus Vienna Biocenter 2

A-1030 Vienna

P: +43-1-20620-303

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.